Tollefsen D M, Blank M K
J Clin Invest. 1981 Sep;68(3):589-96. doi: 10.1172/jci110292.
We have demonstrated that human plasma contains a heparin-dependent inhibitor of thrombin that is distinguishable from antithrombin III (AT III). When a 1:50 dilution of plasma was incubated with greater than or equal to 0.01 U/ml heparin and 1 U/ml 125I-thrombin, the labeled thrombin B-chains became incorporated into two complexes of Mr-96,000 and Mr-85,000 that were separated by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate and beta-mercaptoethanol. Neither complex was detectable at heparin concentrations less than 0.01 U/ml. When a limiting amount of 125I-thrombin was present, the proportion of radioactivity incorporated into each of the two complexes varied with the heparin concentration. Thus, the Mr-85,000 complex predominated at 0.01-5 U/ml heparin, whereas the Mr-96,000 complex predominated at 5-100 U/ml heparin. The Mr-85,000 complex reacted with antibodies to human AT III and comigrated with the purified thrombin-AT III complex. The Mr-96,000 complex did not react with antibodies to AT III or to alpha 1-antitrypsin, and it was detected in normal quantities after incubating 125I-thrombin with plasma immunodepleted of AT III, alpha 2-antiplasmin, alpha 2-macroglobulin, C1 inactivator, alpha 1-antichymotrypsin, or inter-alpha-trypsin inhibitor. The protein that combines with thrombin to form the Mr-96,000 complex was estimated to be present at a minimum concentration of 90 +/- 26 micrograms/ml (mean +/- SD) in identical to any of the known plasma protease inhibitors and that at relatively high heparin concentrations in vitro it reacts with thrombin more rapidly than does AT III.
我们已经证明,人血浆中含有一种依赖肝素的凝血酶抑制剂,它与抗凝血酶III(AT III)不同。当将1:50稀释的血浆与≥0.01 U/ml肝素和1 U/ml 125I-凝血酶一起孵育时,标记的凝血酶B链会形成两种分子量分别为96,000和85,000的复合物,在十二烷基硫酸钠和β-巯基乙醇存在下通过聚丙烯酰胺凝胶电泳进行分离。在肝素浓度低于0.01 U/ml时,这两种复合物均无法检测到。当存在限量的125I-凝血酶时,掺入两种复合物中每种的放射性比例随肝素浓度而变化。因此,在0.01 - 5 U/ml肝素时,分子量85,000的复合物占主导,而在5 - 100 U/ml肝素时,分子量96,000的复合物占主导。分子量85,000的复合物与抗人AT III抗体反应,并与纯化的凝血酶-AT III复合物共迁移。分子量96,000的复合物不与AT III或α1-抗胰蛋白酶抗体反应,并且在用AT III、α2-抗纤溶酶、α2-巨球蛋白、C1灭活剂、α1-抗糜蛋白酶或α-胰蛋白酶间抑制剂免疫去除血浆后与125I-凝血酶孵育,该复合物仍能以正常量检测到。与凝血酶结合形成分子量96,000复合物的蛋白质估计以最低浓度90±26微克/毫升(平均值±标准差)存在,不同于任何已知的血浆蛋白酶抑制剂,并且在体外相对高的肝素浓度下,它与凝血酶的反应比AT III更快。